An Act To Amend Title 18 Of The Delaware Code Relating To Insurance Coverage.
SB22 is a Delaware insurance parity bill that expands and modernizes state coverage requirements for mental health disorders and substance use disorders. It amends Title 18 to require health benefit plans to cover all medically necessary services for these conditions, including inpatient care, residential treatment, intensive outpatient programs, emergency services, mobile crisis response, and medication-assisted treatment. The bill also updates and broadens statutory definitions for mental health disorders, serious mental illness, medically necessary care, utilization review, and related clinical placement tools such as ASAM, LOCUS, CALOCUS-CASII, and ECSII.
The bill places significant limits on how carriers may manage these benefits. It prohibits more burdensome cost-sharing or discriminatory benefit design for behavioral health services, restricts prior authorization and certain utilization review practices, requires emergency medication supplies without prior authorization in specified circumstances, and mandates coverage of certain medications and methadone dispensing fees. It also requires carriers to maintain adequate networks, provide single-case agreements when in-network access is unavailable, disclose parity compliance analyses, and report nonquantitative treatment limitations and related comparative analyses to state regulators. The act applies to policies issued, renewed, modified, altered, amended, or reissued after December 31, 2027.
SB22 would substantially revise Delaware insurance law by strengthening and expanding the behavioral health parity framework in Chapter 33 and Chapter 35 of Title 18. It would impose new coverage mandates, network adequacy standards, disclosure obligations, and reporting requirements on carriers and health insurers, while also incorporating federal parity guidance published in September 2024 as state law. The bill affects health benefit plans, insurers, carriers, covered persons, providers, and the Insurance Commissioner, and it preserves state enforcement authority while stating that the provisions do not create a private right of action.
No committee transcript or vote record was provided, so the bill’s sentiment must be inferred from its sponsorship and structure. The bill appears to have broad bipartisan and cross-chamber sponsorship, suggesting generally favorable legislative interest in expanding mental health and substance use disorder coverage. Its detailed parity and access provisions indicate a policy goal of improving treatment access and limiting insurer barriers, which is typically associated with supportive sentiment among sponsors and behavioral health advocates.
The main points of contention are likely to involve insurer administrative burden, utilization management limits, and the scope of mandated coverage. The bill restricts prior authorization, concurrent review, and the use of more restrictive utilization review criteria, which carriers may view as limiting their ability to manage costs and medical necessity. Another likely issue is the requirement to provide meaningful benefits across classifications and to disclose parity analyses, which could raise compliance and proprietary-information concerns. The bill also draws lines around what must be covered, excluding some non-clinical placements and preserving certain experimental/investigational exclusions, which may be debated by advocates seeking broader coverage and insurers seeking narrower mandates.